Inclisiran (3) – Leqvio®
Primary hypercholesterolaemia or mixed dyslipidaemia
Characteristics
| Start date | 15.10.2026 |
|---|---|
| Resolution | 15.04.2027 – active procedure |
| INN | Inclisiran |
| Brand name | Leqvio® |
| Pharm. company | Novartis Pharma GmbH |
| G-BA Procedure ID | D-1382 |
| Therapeutic area | Metabolic diseases |
| Reason for procedure | Reassessment: §14 (manufacturer request) |
Associated procedures
| Inclisiran (3) | Leqvio® | Novartis Pharma GmbH | Primary hypercholesterolaemia or mixed dyslipidaemia | n.d. | active procedure | |
| Inclisiran (2) | Leqvio® | Novartis Pharma GmbH | Primary hypercholesterolaemia, aged ≥ 12 years to < 18 years | n.d. | active procedure | |
| Inclisiran (1) | Leqvio® | Novartis Pharma GmbH | Primary hypercholesterolaemia or mixed dyslipidaemia | 284,750–410,900 | 100% additional benefit not proven |
<< List of all resolutions